Search - tctmd.com

Displaying 1 - 20 of 99

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

September 09, 2025

No Benefit of Sentinel Device During TAVI: Updated Meta-analysis

News Conference News NY Valves 2025

No Benefit of Sentinel Device During TAVI: Updated Meta-analysis

July 04, 2025

Two Trials Boost Intra-arterial Lytics After Stroke Thrombectomy

News Conference News ISC 2025

Two Trials Boost Intra-arterial Lytics After Stroke Thrombectomy

February 11, 2025

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

News Conference News TCT 2024

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

Yael L. Maxwell

October 29, 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

News Conference News TCT 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

October 29, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

News Conference News ISET 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

January 25, 2023

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

News Conference News TCT 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

September 17, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

Less Death, Major Bleeding With Transradial Access: Meta-analysis

News Conference News ESC 2022

Less Death, Major Bleeding With Transradial Access: Meta-analysis

Michael O'Riordan

August 29, 2022

Distal Radial Access Doesn’t Lower Risk of Occlusion: DISCO RADIAL

News Conference News EuroPCR 2022

Distal Radial Access Doesn’t Lower Risk of Occlusion: DISCO RADIAL

Michael O'Riordan

May 19, 2022

Potassium Ferrate Patch Speeds Hemostasis, Discharge After Radial PCI

News Conference News EuroPCR 2022

Potassium Ferrate Patch Speeds Hemostasis, Discharge After Radial PCI

May 17, 2022

Nitroglycerin Given Early or Late Fails to Prevent Radial Artery Occlusion: PATENS

News Conference News ACC 2022

Nitroglycerin Given Early or Late Fails to Prevent Radial Artery Occlusion: PATENS

Michael O'Riordan

March 25, 2022

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

November 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.